Aug 13, 2020
Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor
Jun 05, 2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
May 15, 2020
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
May 07, 2020
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
Feb 25, 2020
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
Feb 15, 2020
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium
Jan 14, 2020
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Jan 09, 2020
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jan 08, 2020
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Jan 06, 2020
Mirati Therapeutics Announces Executive Management Changes
Nov 04, 2019
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
Oct 23, 2019
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Oct 17, 2019
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Aug 15, 2019
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
Aug 05, 2019
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
Jul 09, 2019
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
Jun 25, 2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jun 24, 2019
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Apr 29, 2019
Mirati Therapeutics Reports First Quarter 2019 Financial Results
Apr 01, 2019
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference